FI4054584T3 - Menetelmiä merkittävien sydän- ja verisuoniperäisten haittatapahtumien (mace) hoitamiseksi ja/tai ehkäisemiseksi bet-bromodomeenin estäjän ja natriumista riippuvaisen glukoosin kuljetusproteiinin 2:n estäjän yhdistelmällä - Google Patents
Menetelmiä merkittävien sydän- ja verisuoniperäisten haittatapahtumien (mace) hoitamiseksi ja/tai ehkäisemiseksi bet-bromodomeenin estäjän ja natriumista riippuvaisen glukoosin kuljetusproteiinin 2:n estäjän yhdistelmälläInfo
- Publication number
- FI4054584T3 FI4054584T3 FIEP20884269.0T FI20884269T FI4054584T3 FI 4054584 T3 FI4054584 T3 FI 4054584T3 FI 20884269 T FI20884269 T FI 20884269T FI 4054584 T3 FI4054584 T3 FI 4054584T3
- Authority
- FI
- Finland
- Prior art keywords
- compound
- use according
- subject
- inhibitor
- mace
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930860P | 2019-11-05 | 2019-11-05 | |
| PCT/IB2020/000912 WO2021090061A1 (en) | 2019-11-05 | 2020-11-04 | Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4054584T3 true FI4054584T3 (fi) | 2025-08-22 |
Family
ID=75849803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20884269.0T FI4054584T3 (fi) | 2019-11-05 | 2020-11-04 | Menetelmiä merkittävien sydän- ja verisuoniperäisten haittatapahtumien (mace) hoitamiseksi ja/tai ehkäisemiseksi bet-bromodomeenin estäjän ja natriumista riippuvaisen glukoosin kuljetusproteiinin 2:n estäjän yhdistelmällä |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12551484B2 (https=) |
| EP (1) | EP4054584B1 (https=) |
| JP (1) | JP7502811B2 (https=) |
| KR (1) | KR102935008B1 (https=) |
| CN (1) | CN114650824A (https=) |
| AU (1) | AU2020377539B2 (https=) |
| BR (1) | BR112022008223A2 (https=) |
| CA (1) | CA3160147A1 (https=) |
| DK (1) | DK4054584T3 (https=) |
| ES (1) | ES3042146T3 (https=) |
| FI (1) | FI4054584T3 (https=) |
| HU (1) | HUE073043T2 (https=) |
| IL (1) | IL292696B1 (https=) |
| MX (1) | MX2022005029A (https=) |
| PL (1) | PL4054584T3 (https=) |
| PT (1) | PT4054584T (https=) |
| TW (1) | TWI867086B (https=) |
| WO (1) | WO2021090061A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114650824A (zh) | 2019-11-05 | 2022-06-21 | 雷斯韦洛吉克斯公司 | 用bet溴结构域抑制剂和钠依赖性葡萄糖转运蛋白2抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法 |
| US20230398137A1 (en) * | 2020-10-30 | 2023-12-14 | Resverlogix Corp. | Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| US20220370485A1 (en) * | 2021-01-14 | 2022-11-24 | Lexicon Pharmaceuticals, Inc. | Compounds and methods for treating or preventing cardiovascular diseases and conditions |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8410109B2 (en) | 2005-07-29 | 2013-04-02 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| PT2118074E (pt) | 2007-02-01 | 2014-03-20 | Resverlogix Corp | Compostos para a prevenção e tratamento de doenças cardiovasculares |
| SI2346837T1 (sl) | 2008-06-26 | 2015-05-29 | Resverlogix Corporation | Postopki pripravljanja kinazolinonskih derivatov |
| KR101913109B1 (ko) | 2009-03-18 | 2018-10-31 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| MX2011009852A (es) | 2009-03-27 | 2011-09-29 | Bristol Myers Squibb Co | Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv. |
| US9757368B2 (en) | 2009-04-22 | 2017-09-12 | Resverlogix Corp. | Anti-inflammatory agents |
| JP2012528170A (ja) | 2009-05-27 | 2012-11-12 | ブリストル−マイヤーズ スクイブ カンパニー | 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法 |
| CA2851996C (en) | 2011-11-01 | 2020-01-07 | Resverlogix Corp. | Pharmaceutical compositions for substituted quinazolinones |
| US20130281398A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
| EP4678242A3 (en) | 2013-04-18 | 2026-03-18 | Boehringer Ingelheim International GmbH | Pharmaceutical composition, methods for treating and uses thereof |
| HK1219434A1 (zh) * | 2013-08-21 | 2017-04-07 | Resverlogix Corp. | 用於加速斑块消退的组合物和治疗方法 |
| AU2014310371A1 (en) | 2013-08-21 | 2016-03-10 | Resverlogix Corp. | Compositions and therapeutic methods for accelerated plaque regression |
| TW201625605A (zh) * | 2014-04-04 | 2016-07-16 | 賽諾菲公司 | 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類 |
| US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
| EP3355922A2 (en) * | 2015-10-02 | 2018-08-08 | Dana Farber Cancer Institute, Inc. | Combination therapy of bromodomain inhibitors and checkpoint blockade |
| EP3553058A1 (en) | 2016-12-09 | 2019-10-16 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of bromodomain protein inhibitor drug, preparation method and use thereof |
| US11419883B2 (en) | 2017-05-05 | 2022-08-23 | The Regents Of The University Of California | Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes |
| CN114650824A (zh) | 2019-11-05 | 2022-06-21 | 雷斯韦洛吉克斯公司 | 用bet溴结构域抑制剂和钠依赖性葡萄糖转运蛋白2抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法 |
| JP7763761B2 (ja) | 2020-01-08 | 2025-11-04 | レスバーロジックス コーポレイション | Ｂｅｔブロモドメイン阻害剤およびジペプチジルペプチダーゼ４阻害剤の組合せによる主要有害心血管イベント（ｍａｃｅ）の治療方法および／または予防方法 |
| US20230398137A1 (en) * | 2020-10-30 | 2023-12-14 | Resverlogix Corp. | Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
| CA3197706A1 (en) | 2020-10-30 | 2022-05-05 | Resverlogix Corp. | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
-
2020
- 2020-11-04 CN CN202080076646.1A patent/CN114650824A/zh active Pending
- 2020-11-04 HU HUE20884269A patent/HUE073043T2/hu unknown
- 2020-11-04 WO PCT/IB2020/000912 patent/WO2021090061A1/en not_active Ceased
- 2020-11-04 BR BR112022008223A patent/BR112022008223A2/pt unknown
- 2020-11-04 PT PT208842690T patent/PT4054584T/pt unknown
- 2020-11-04 EP EP20884269.0A patent/EP4054584B1/en active Active
- 2020-11-04 FI FIEP20884269.0T patent/FI4054584T3/fi active
- 2020-11-04 AU AU2020377539A patent/AU2020377539B2/en active Active
- 2020-11-04 PL PL20884269.0T patent/PL4054584T3/pl unknown
- 2020-11-04 US US17/774,657 patent/US12551484B2/en active Active
- 2020-11-04 DK DK20884269.0T patent/DK4054584T3/da active
- 2020-11-04 KR KR1020227019038A patent/KR102935008B1/ko active Active
- 2020-11-04 JP JP2022525779A patent/JP7502811B2/ja active Active
- 2020-11-04 CA CA3160147A patent/CA3160147A1/en active Pending
- 2020-11-04 TW TW109138504A patent/TWI867086B/zh active
- 2020-11-04 ES ES20884269T patent/ES3042146T3/es active Active
- 2020-11-04 IL IL292696A patent/IL292696B1/en unknown
- 2020-11-04 MX MX2022005029A patent/MX2022005029A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220098757A (ko) | 2022-07-12 |
| IL292696B1 (en) | 2026-01-01 |
| EP4054584B1 (en) | 2025-07-09 |
| IL292696A (en) | 2022-07-01 |
| US20220370452A1 (en) | 2022-11-24 |
| BR112022008223A2 (pt) | 2022-09-06 |
| HUE073043T2 (hu) | 2025-12-28 |
| MX2022005029A (es) | 2022-07-12 |
| TW202131924A (zh) | 2021-09-01 |
| AU2020377539A1 (en) | 2022-05-19 |
| CN114650824A (zh) | 2022-06-21 |
| ES3042146T3 (en) | 2025-11-18 |
| DK4054584T3 (en) | 2025-09-01 |
| CA3160147A1 (en) | 2021-05-14 |
| TWI867086B (zh) | 2024-12-21 |
| EP4054584A4 (en) | 2023-11-08 |
| EP4054584A1 (en) | 2022-09-14 |
| KR102935008B1 (ko) | 2026-03-09 |
| PT4054584T (pt) | 2025-07-16 |
| AU2020377539B2 (en) | 2025-05-29 |
| JP2023500685A (ja) | 2023-01-10 |
| PL4054584T3 (pl) | 2025-11-03 |
| WO2021090061A1 (en) | 2021-05-14 |
| US12551484B2 (en) | 2026-02-17 |
| JP7502811B2 (ja) | 2024-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2024205084B2 (en) | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative | |
| US12364700B2 (en) | Medical use of pharmaceutical combination or composition | |
| FI4054584T3 (fi) | Menetelmiä merkittävien sydän- ja verisuoniperäisten haittatapahtumien (mace) hoitamiseksi ja/tai ehkäisemiseksi bet-bromodomeenin estäjän ja natriumista riippuvaisen glukoosin kuljetusproteiinin 2:n estäjän yhdistelmällä | |
| JP2021095409A (ja) | 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用 | |
| CA2293415C (en) | Compositions for treating and preventing arterial thrombosis and use of a factor xa inhibitor on its own and/or combined with a platelet antiaggregating agent | |
| IL274943B2 (en) | Combination of a 4-pyrimidinsulfamide derivative with an SGLT-2 inhibitor for the treatment of endothelin-related diseases | |
| JP2002518448A (ja) | 高血中コレステロールを治療する組成物および方法 | |
| JP2023500685A5 (https=) | ||
| WO2021014351A1 (en) | Treatment comprising sglt inhibitors, e.g. sglt 1/2 inhibitors | |
| JP2023507364A (ja) | インテグリン阻害剤を使用する肝疾患の治療の組み合わせ | |
| US20050119337A1 (en) | Methods of application of Schisandrin B in the preparation of anticancer medications | |
| Filipiak et al. | STRUGGLE FOR. Italian-Polish-Spanish-Uzbek-Vietnamese Expert Forum Position Paper 2023 for better control of classical modifiable risk factors in clinical practice | |
| Cheng | To market, to market-1995 | |
| CA2493208A1 (en) | Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure | |
| Francis et al. | Reversible cardiotoxicity with tyrosine kinase inhibitors | |
| JP2023509186A5 (https=) | ||
| US20250134917A1 (en) | Compositions and methods of regenerating heart tissues with aminoglycosides | |
| Tichy et al. | Significant sirolimus and dronedarone interaction in a kidney transplant recipient | |
| RU2025105192A (ru) | Фармацевтическая композиция, содержащая метаболит энавоглифлозина, и ее применение | |
| HOANG et al. | The Efficacy and Safety of SGLT-2 Inhibitors in Patients With Type 2 Diabetes. | |
| EA047426B1 (ru) | Способы лечения и/или предотвращения серьезных нежелательных сердечно-сосудистых явлений (снсся) с помощью комбинации ингибитора бромодомена bet и ингибитора натрий-глюкозного котранспортера 2-го типа | |
| TH2001003051A (th) | การรวมกันของอนุพันธ์ 4-ไพริมิดีนซัลฟาไมด์กับตัวยับยั้ง sglt-2 สำหรับการบำบัดโรคที่เกี่ยวข้องกับเอนโดทีลิน | |
| RU2019139082A (ru) | Твердые композиции для перорального введения | |
| HUE030538T2 (en) | Use of a vasopeptidase inhibitor for the treatment of pulmonary arterial hypertension |